Interferon beta (IFN-) therapy is one of the most commonly prescribed immunomodulatory therapies in relapsing-remitting multiple sclerosis (RRMS). A reversible cerebral vasoconstriction syndrome (RCVS), associated with IFN- use, has been recently described. For this reason, we tested the effect of once a week intramuscular administration of IFN--1A on the function of cerebral vessels in a cohort of RRMS patients. Using transcranial Doppler (TCD) ultrasound, we measured the mean blood flow velocity (MFV) in intracranial vessels 10 h after IFN- administration. Measurements showed a significant increase in MFV compared to the baseline values in some vessels.
Relationship between Interferon Beta-1A administration and intracranial vascular tone regulation in patients with relapsing-remitting multiple sclerosis: a pilot study
Dattola, Vincenzo
Primo
Conceptualization
;Bonanno, LillaInvestigation
;Naro, AntoninoFormal Analysis
;Chillura, AntoninoInvestigation
;Sessa, EdoardoInvestigation
;Fama', Fausto;Quartarone, AngeloMembro del Collaboration Group
;Calabro', Rocco SalvatoreData Curation
;Marino, SilviaInvestigation
;Russo, MargheritaUltimo
Investigation
2017-01-01
Abstract
Interferon beta (IFN-) therapy is one of the most commonly prescribed immunomodulatory therapies in relapsing-remitting multiple sclerosis (RRMS). A reversible cerebral vasoconstriction syndrome (RCVS), associated with IFN- use, has been recently described. For this reason, we tested the effect of once a week intramuscular administration of IFN--1A on the function of cerebral vessels in a cohort of RRMS patients. Using transcranial Doppler (TCD) ultrasound, we measured the mean blood flow velocity (MFV) in intracranial vessels 10 h after IFN- administration. Measurements showed a significant increase in MFV compared to the baseline values in some vessels.File | Dimensione | Formato | |
---|---|---|---|
Relationship between IFN Beta-1A and RRMS 2017.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
1.34 MB
Formato
Adobe PDF
|
1.34 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.